Ambryon Biosciences

AAVmyo Serotype

Peptide-displaying AAV9 capsid variant (AAV9P1) carrying the 7-mer peptide P1 (RGDLGLS) on the capsid surface. Identified in a barcoded in vivo screen of 183 pre-selected capsids in mice. Transduces skeletal muscle, diaphragm and heart after intravenous injection, with lower liver transduction than AAV9.

OriginAAV9 capsid with the P1 peptide inserted in variable region VIII

Characteristics

After intravenous injection of 1e11 vg of CMV-eyfp vectors into C57BL/6 mice, eyfp mRNA is 61-fold (diaphragm), 17-fold (quadriceps femoris) and 11-fold (heart) higher than with AAV9 and 9-fold lower in liver (1 week). With SPc5-12-driven firefly luciferase (4e10 vg, CB17-SCID mice, 4 weeks), mRNA is 11.6-fold (diaphragm), 37.8- to 50.1-fold (skeletal muscles) and 5.8-fold (heart) higher than AAV9 and 23.2-fold lower in liver. Titers are comparable to AAV9, and the capsid is compatible with affinity-column purification.

Applications

Intravenous gene delivery to skeletal muscle, diaphragm and heart in mice (C57BL/6 and CB17-SCID). Micro-dystrophin from AAVMYO is expressed at higher levels than from AAV9 in quadriceps of mdx mice 4 weeks after 2e11 or 1e12 vg per mouse. Transduces type I, IIa and IIb muscle fibers in quadriceps femoris.

Limitations

Tested in mice only; the cellular receptor is unknown, and the RGD motif in P1 suggests integrin binding as a hypothesis. Also transduces white fat in a subset of mice. The P504A/G505A liver-detargeted variant AAVMYO_LD is less active in muscle. Fold-changes versus AAV9 vary with mouse strain and dose.

Tropism

Skeletal muscle (quadriceps femoris, biceps), diaphragm, heart (mouse, intravenous)

Sequence1 bp

Sign in to view the full sequence.

Sign in

References

  1. 1.Weinmann et al. (2020). Identification of a myotropic AAV by massively parallel in vivo evaluation of barcoded capsid variants. Nat Commun — Weinmann 2020 AAVMYO

Identifiers & revision